UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **June 13, 2018**

CARDAX, INC.
(Exact name of registrant as specified in its charter)

Delaware	**333-181719**	**45-4484428**
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2800 Woodlawn Drive, Suite 129, Honolulu, Hawaii 96822
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(808) 457-1400**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

ITEM 7.01 REGULATION FD DISCLOSURE.

On June 13, 2018, Cardax, Inc. (the "Company") issued a press release announcing that it engaged a service provider to launch the Company's orphan drug development program.

In accordance with General Instruction B.2 of Form 8-K, the information set forth herein and in Exhibit 99.1 hereto is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of the Exchange Act. The information set forth in Item 7.01 of this Current Report on Form 8-K shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Safe Harbor

This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No.	Description
99.1	Press Release, dated June 13, 2018 (furnished herewith)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 13, 2018

CARDAX, INC.

By: */s/ David G. Watumull*
David G. Watumull
Chief Executive Officer and President

Cardax Engages Industry Veteran Fred Sancilio, Ph.D. to Launch Orphan Drug Development Program

INFLAMMATION'S MAJOR ROLE IN CHRONIC ORPHAN DISEASES SUPPORTS PROGRAM'S STRONG POTENTIAL

HONOLULU, June 13, 2018 /PRNewswire/ — Cardax, Inc. (OTCQB: CDXI) announced today that it engaged industry veteran and orphan drug expert, Frederick D. Sancilio, Ph.D., to launch the Company's orphan drug development program. Dr. Sancilio has over 40 years of pharmaceutical industry experience, including founding and running a leading contract research organization that contributed to more than 2,000 drug product registrations in the U.S., Asia, and Europe.

Orphan drugs are defined by federal statute as treatments for diseases with fewer than 200,000 patients in the U.S. While clinical trials are required for the approval of an orphan drug, the U.S. Food and Drug Administration ("FDA") may designate an orphan drug candidate as a potential orphan drug early in the development process, often prior to initiation of clinical trials. Receipt of an "Orphan Drug Designation" from the FDA can be a significant factor in financing and/or partnership opportunities to support the development of an orphan drug candidate.

The major role of inflammation in chronic disease, including rare (orphan) diseases, supports the strong potential of safe anti-inflammatory treatments for orphan indications. Dr. Sancilio will focus first on obtaining an Orphan Drug Designation for a safe anti-inflammatory orphan drug candidate from the Company's astaxanthin platform.

Cardax believes an orphan drug development program provides an opportunity to address major unmet medical needs in underserved populations and typically offers a number of other benefits, including smaller, less costly clinical trials, leading to a more efficient regulatory path. In addition, potential tax credits and research grants may be available, and importantly, seven-year market exclusivity is granted by the FDA upon orphan drug approval.

"We feel the efficient, economical, and potentially rewarding orphan drug pathway makes a lot of sense for Cardax as a pharmaceutical development program," said Cardax President and CEO David G Watumull. "We are pleased and honored to be working with someone with Fred's background and experience to lead this important program."

"After reviewing the research on astaxanthin and Cardax's wealth of knowledge regarding astaxanthin's potential to treat several rare orphan diseases, I am delighted to join their team and launch this program," added Dr. Sancilio. "Having worked in both rare orphan disease research and inflammation medicaments, I look forward to continue helping patients who have limited or no pharmaceutical treatment options."

The Company plans to submit an orphan drug designation application to the FDA within twelve months. This application primarily focuses on providing evidence supporting the size of the orphan population and also includes a rationale for the drug's potential efficacy in the orphan indication. By statute the FDA has 90 days to respond to the application but may require additional data or reject the application outright.

About Cardax

Cardax devotes substantially all of its efforts to developing and commercializing dietary supplements and pharmaceuticals. Cardax is initially focusing on astaxanthin, which is a powerful and safe naturally occurring anti-inflammatory compound. The safety and efficacy of Cardax's products have not been directly evaluated in clinical trials or confirmed by the FDA.

About Astaxanthin

Astaxanthin is a clinically studied compound with safe anti-inflammatory activity supported by more than 1,600 peer-reviewed papers and more than fifty human proof-of-concept studies, including more than twenty randomized, double-blind, placebo-controlled clinical trials.

Media and Investors

Janice Kam
1-808-457-1400
press@cardaxpharma.com

Safe Harbor

This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.